BIORCHESTRA is a preclinical stage biotech company and a novel RNA-based therapeutics company focusing on neurodegenerative diseases and rare genetic diseases through novel target discovery and a novel drug delivery system for the targeting of specific organs, such as the brain and the muscle. BMD-001, Alzheimer’s disease modifying therapy, is an antisense oligonucleotide (ASO) encapsulated in BDDS, a proprietary PEG-polyion micelle based-brain shuttle technology. Biomarker-driven clinical trial for BMD-001 is planned to initiate in 2023. This has led to the expansion of its application to ALS and Parkinson's disease. Clinical trials for miRStra®, Alzheimer's disease pre-screening kit detecting pathogenic miRNA in blood or saliva is currently ongoing in South Korea.